Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.5 - $2.5 $13,026 - $65,132
-26,053 Reduced 18.23%
116,847 $64,000
Q2 2022

Aug 15, 2022

BUY
$2.08 - $7.2 $297,232 - $1.03 Million
142,900 New
142,900 $417,000

Others Institutions Holding XLO

About Xilio Therapeutics, Inc.


  • Ticker XLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,471,600
  • Market Cap $25.8M
  • Description
  • Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...
More about XLO
Track This Portfolio

Track Laurion Capital Management LP Portfolio

Follow Laurion Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Laurion Capital Management LP with notifications on news.